Drug intelligence / Profile preview

STABHA

Development stage: Phase 3
Administration: Intra-articular Injection, Peri-tendinous Injection, Soft Tissue Injection

Overview

STABHA (Soft Tissue Adapted Biocompatible Hyaluronic Acid) is a specialized form of hyaluronic acid developed in 2008 for the treatment of damaged musculoskeletal soft tissue. It is designed to be biocompatible and efficient in supporting regeneration processes in ligaments and tendons after acute or chronic injuries. STABHA-containing preparations have demonstrated therapeutic efficacy in clinical trials for common musculoskeletal disorders and injuries such as talocrural sprain, tennis elbow, and rotator cuff tendinopathy.

Brand names: SportVis
Other names: Soft Tissue Adapted Biocompatible Hyaluronic Acid

Targets

CD44 (CD44 antigen)HMMR

Beyond the preview

Go deeper on STABHA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STABHA.

Explore the full profile